Intensity Therapeutics shares jump 11.93% intraday after announcing two presentations on INT230-6 at the 2025 San Antonio Breast Cancer Symposium.

Intensity Therapeutics Inc. surged 11.93% intraday following the announcement of two presentations at the 2025 San Antonio Breast Cancer Symposium, highlighting its lead drug candidate INT230-6. The presentations detailed clinical data on INT230-6’s potential as an anthracycline-free breast cancer therapy and its intratumoral efficacy in triple-negative breast cancer. These updates underscored progress in late-stage trials and the drug’s mechanism to induce immune responses, positioning it as a transformative treatment. The news reinforced investor confidence in the company’s pipeline and its ability to address unmet medical needs, outweighing neutral financial announcements about an expanded ATM offering. The timing of the presentations (Dec. 11–12) and positive clinical signals drove immediate optimism in the biotech sector.